Retatrutide + MOTS-c Peptide Stack: Dosing Guide Reta + Mitochondrial Pair (2026)

The retatrutide + MOTS-c stack pairs two research compounds that work on very different parts of fat metabolism. Retatrutide is Eli Lilly's investigational triple-receptor agonist - one weekly injection that acts on GLP-1, GIP, and glucagon receptors at once to cut appetite, improve insulin signaling, and raise energy use. MOTS-c is a small 16-amino-acid peptide encoded inside your own mitochondrial DNA. It is added to support what happens inside your cells while retatrutide drives the calorie deficit.

The community calls this combo a few different names: the Metabolic Super Stack, the Elite Metabolic Stack, or just reta + MOTS-c. They all mean the same two-compound protocol. This page covers what the stack is, how researchers usually schedule it, the reconstitution math for both vials, what to watch for, and how it compares to other retatrutide pairings.

Need broader context on combining peptides? See PepPal's stacking safety guide. For supplier and quality-control sourcing, see the PepPal supplier directory.

The retatrutide + MOTS-c stack is a two-compound research protocol. It pairs a top-of-class metabolic peptide with a much smaller peptide that targets the cellular layer of fat burning. The plain-English version: retatrutide tells your body to release fat from storage and to want less food. MOTS-c helps your cells actually burn the fat that retatrutide is releasing.

Researchers reach for this combination when the goal is not just appetite control but metabolic efficiency during a hard fat-loss phase. The simpler comparison is the cagrilintide + retatrutide stack, which adds extra satiety. The more complex one is the Advanced Recomp Stack, which layers in a growth-hormone secretagogue for lean mass.

Retatrutide (LY3437943) is a once-weekly triple agonist. It hits three receptors at once: GLP-1 (cuts appetite, slows stomach), GIP (improves insulin signaling), and glucagon (raises energy expenditure and fat mobilization). In the Phase 3 TRIUMPH-4 trial, retatrutide at 12 mg produced 28.7% body weight loss at 68 weeks vs 2.1% for placebo.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide. It activates AMPK - the cellular energy sensor that flips muscle cells from preferring glucose to preferring fat as fuel. AMPK is the same pathway activated by exercise and metformin. MOTS-c has no completed native-peptide human efficacy trial. The closest human data is from CB4211, an analog that completed Phase 1a/1b safety testing.

Retatrutide is one of the most powerful metabolic compounds ever tested in humans, but it acts on systemic hormones. It does not reach inside your skeletal muscle cells to tell mitochondria what to burn. MOTS-c is added to fill that specific gap. The combined logic is:

There is no pre-blended retatrutide + MOTS-c vial on the market as of May 2026. The two compounds have very different stability windows once reconstituted, so they are dosed from separate vials. Both compounds are subcutaneous only - no oral or sublingual options.

The most consistent recommendation across community protocols is to run retatrutide alone for the first 4 weeks at 1 mg weekly, confirm GI tolerance, then add MOTS-c at Week 5. Retatrutide's glucagon arm produces more nausea than pure GLP-1 compounds, so stabilizing it first makes it much easier to tell where any new symptom is coming from.

Each compound is reconstituted on its own. The math below mirrors the Retatrutide protocol page and the MOTS-c protocol page so the numbers match across the site.

Retatrutide is the workhorse of this stack. It does the heavy lifting on appetite, insulin signaling, and energy expenditure. The case for adding MOTS-c is that retatrutide alone leaves a gap inside the cell. Here is how each pathway is supposed to fit together.

MOTS-c activates AMP-activated protein kinase (AMPK), the energy sensor that flips muscle cells from preferring glucose to preferring fat. Retatrutide releases fatty acids from storage; MOTS-c reprograms the mitochondria to actually burn them. Without that downstream switch, mobilized fat can simply circulate and end up re-stored. This is the single most cited reason community protocols pair the two.

Both compounds improve insulin signaling, but at different layers. Retatrutide acts on the GIP receptor at the islet cell, where insulin is made. MOTS-c works further downstream by improving glucose uptake into skeletal muscle independent of insulin spikes. In animal models, MOTS-c restored insulin sensitivity in aged and high-fat-fed mice at the muscle level - the same tissue where late-stage GLP-1 protocols often see metabolic slowdown.

Several preclinical studies link MOTS-c to reduced myostatin signaling. Myostatin is the protein that limits muscle growth. Less myostatin activity makes it easier to hold onto muscle during a deficit. This is the most speculative of the three pathways - direct human evidence is limited - but it is the rationale most often given for pairing MOTS-c with retatrutide specifically rather than with a slower-deficit compound.

MOTS-c activates many of the same pathways as exercise: better endurance, better metabolic flexibility, more stress tolerance. In one preclinical study, old mice treated with MOTS-c doubled their treadmill running time and outperformed middle-aged comparators. During a deep retatrutide deficit - when fatigue and lower training capacity are common - this exercise-mimetic effect is the reason MOTS-c dosing usually lines up with training days.

If the goal is purely appetite-driven fat loss, retatrutide alone produced 28.7% body weight loss at the top dose in TRIUMPH-4 - no added compound needed. Researchers add MOTS-c when the goal is what happens to muscle and mitochondrial function during that deficit. That usually means advanced subjects, plateaued protocols, or longer cycles where metabolic adaptation becomes the limiting factor.

Each compound has its own safety profile. Retatrutide has been studied in Phase 3. MOTS-c safety data comes from animals plus one analog (CB4211) human Phase 1 trial. The combination has not been tested in any trial, so the combined safety picture is built from adding each compound's known signals together.

Standard conservative practice excludes anyone with active gastrointestinal disease, type 1 diabetes, prior pancreatitis, medullary thyroid carcinoma history, or active cancer from any retatrutide protocol. Add caution for anyone using metformin, berberine, or other AMPK-active medications when MOTS-c is in the picture.

Phase 3 TRIUMPH-4 (NCT05931367, 445 participants, 68 weeks) reported 28.7% body weight loss at 12 mg, 26.4% at 9 mg, vs 2.1% placebo. Phase 2 (Jastreboff et al., NEJM 2023) reported 24.2% weight loss at 48 weeks at 12 mg. The TRIUMPH program has six more Phase 3 readouts expected through 2026.

See the Retatrutide protocol page for the standalone reference.

No completed human efficacy trial of the native peptide. Strong preclinical coverage: improved insulin sensitivity in aged and high-fat-fed mice (Lee et al., Cell Metabolism 2015) and roughly doubled treadmill running time in old mice (Reynolds et al., Nature Communications 2021). The closest human data is from CB4211, an analog that completed a Phase 1a/1b safety trial (NCT03998514) with well-tolerated SubQ dosing and favorable liver-enzyme and glucose trends.

See the MOTS-c protocol page for the standalone reference.

The retatrutide + MOTS-c combination is a coverage model: retatrutide drives the systemic deficit through three hormone receptors, and MOTS-c targets the cellular layer where that deficit either gets converted to fat oxidation or stalls into adaptation. The mechanism map is consistent. The combined human evidence does not yet exist.